GlassScriptPhysician profile
Kaleyathodi N Bhat
NPI 1316904725
$4,776.33
in general payments reported to CMS, 2019-2025
32 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,424 · 2020: $429 · 2021: $378 · 2022: $435 · 2023: $476 · 2024: $331 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,200.57 | 2019-2025 | Fasenra |
| Glaxosmithkline, LLC. | $1,110.58 | 2019-2025 | Nucala |
| Amgen INC. | $338.55 | 2019-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $326.56 | 2019-2024 | Dupixent |
| Genzyme Corporation | $270.28 | 2019-2021 | |
| Intuitive Surgical, INC. | $214.49 | 2019 | |
| Novo Nordisk INC | $171.82 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $159.83 | 2019-2022 | |
| Inspire Medical Systems, INC. | $145.18 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.62 | 2019 | |
| Resmed Corp | $68.43 | 2023 | |
| Optinose US, INC. | $65.93 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $62.58 | 2019-2025 | |
| Radius Health, INC. | $52.07 | 2019-2020 | |
| Irhythm Technologies, INC. | $46.17 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $37.94 | 2019 | |
| Lilly USA, LLC | $33.84 | 2019 | |
| Kaleo, INC. | $33.37 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $29.71 | 2025 | Lumryz |
| Pfizer INC. | $28.30 | 2020-2021 | |
| Corcept Therapeutics | $28.16 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $27.90 | 2024 | Fisher & Paykel Healthcare |
| Takeda Pharmaceuticals U.S.A., INC. | $25.56 | 2022 | |
| Csl Behring | $25.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.82 | 2019 | |
| Abbvie INC. | $24.27 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.45 | 2020 | |
| Alfasigma USA, INC. | $19.26 | 2020 | |
| Genentech USA, INC. | $18.52 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.96 | 2020 | |
| Mannkind Corporation | $15.26 | 2022 | |
| Insulet Corporation | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleyathodi Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.